A phase I trial of irinotecan (CPT-11) with amifostine in patients with metastatic colorectal cancer

By Wakelee Heather   Fisher George  

Investigational New Drugs, Vol. 23, Iss. 3, 2005-06 ,pp. : 241-242

Springer Publishing Company

Access to resources Recommend Favorite

Topoisomerase I inhibition with topotecan: pharmacologic and clinical issues

By Arun B.   Frenkel E.P.  

Expert Opinion on Pharmacotherapy, Vol. 2, Iss. 3, 2001-03 ,pp. : 491-505

Informa Healthcare

Access to resources Recommend Favorite

Toxicity of the topoisomerase I inhibitors

By Seiter Karen  

Expert Opinion on Drug Safety, Vol. 4, Iss. 1, 2005-01 ,pp. : 45-53

Informa Healthcare

Access to resources Recommend Favorite

Transition Metal-Mediated Liposomal Encapsulation of Irinotecan (CPT-11) Stabilizes the Drug in the Therapeutically Active Lactone Conformation

By Ramsay Euan   Alnajim Jehan   Anantha Malathi   Taggar Aman   Thomas Anitha   Edwards Katarina   Karlsson Göran   Webb Murray   Bally Marcel  

Pharmaceutical Research, Vol. 23, Iss. 12, 2006-12 ,pp. : 2799-2808

Springer Publishing Company

Access to resources Recommend Favorite

Activity of weekly irinotecan (CPT-11) in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes

By Sánchez Rosa   Esteban Emilio   Palacio Isabel   Fernández Yolanda   Muñiz Isabel   Vieitez Jose M.   Fra Joaquin   Blay Pilar   Villanueva Noemí   Uña Esther   Mareque Beatriz   Estrada Enrique   Buesa Jose M.   Lacave Angel J.  

Investigational New Drugs, Vol. 21, Iss. 4, 2003-11 ,pp. : 459-463

Springer Publishing Company

Access to resources Recommend Favorite